Rockwell Medical Inc.
TypePublic company
Nasdaq: RMTI
Russell 2000 Index component
IndustryPharmaceutical industry
Founded1996 (1996)
HeadquartersWixom, Michigan
Key people
Stuart Paul, President and CEO
Ajay Gupta, Chief Scientific Officer
Raymond D. Pratt, Chief Medical Officer
RevenueIncrease $63 million (2018)
Decrease -$32 million (2018)
Total assetsDecrease $52 million (2018)
Total equityDecrease $27 million (2018)
Number of employees
269 (2018)
Websitewww.rockwellmed.com
Footnotes / references
[1]

Rockwell Medical Inc. is a company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).

The company's primary customers are dialysis providers.[1]

Products

Triferic

Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transported it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market.[2][3][4] In February 2014, the Company completed its long-term safety study for Triferic.[5]

Calcitriol

Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.[6]

Hemodialysis Concentrates

Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.[6]

Iron (III) pyrophosphate

One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.

References

  1. 1 2 "Rockwell Medical Inc. 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. ↑ "Triferic Pharmacokinetics Characterized". Renal and Urology News. 2017-04-20.
  3. ↑ "FDA Drug information" (PDF). FDA.
  4. ↑ "NASDAQ SEC Filing". SEC.
  5. ↑ "Rockwell Medical Completes Long-Term Safety Study for Triferic(TM)".
  6. 1 2 "NASDAQ | SEC Filing". secfilings.nasdaq.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.